I-Mab’s Promising Q3 Results and Strategic Moves
I-Mab, a U.S.-based biotech firm, reported promising financial and clinical advancements in its third-quarter 2024 results. The company is set to initiate a Phase 2 study for uliledlimab in lung ...
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...